1210-96-4

Basic information

• Product Name: 1,5-Dimethoxy-2,4-dinitrobenzene
• Synonyms: Benzene,1,5-dimethoxy-2,4-dinitro-
• CAS NO: 1210-96-4
• Molecular Formula: C₈H₈N₂O₆
• Molecular Weight: 228.16
• Mol File: 1210-96-4.mol

Chemical Properties

• Boiling Point: 410.4 °C at 760 mmHg
• Flash Point: 205.7 °C
• Appearance: /
• Density: 1.416 g/cm³
• Vapor Pressure: 1.43E-06mmHg at 25°C
• Refractive Index: 1.567
• CAS DataBase Reference: 1,5-Dimethoxy-2,4-dinitrobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1,5-Dimethoxy-2,4-dinitrobenzene(1210-96-4)
• EPA Substance Registry System: 1,5-Dimethoxy-2,4-dinitrobenzene(1210-96-4)

Safety Data

• Statements: R20/21/22:Harmful by inhalation, in contact with skin and if swallowed.; R5:Heating may cause an explosion.
• Safety Statements: S22:Do not inhale dust.; S36/37/39:Wear suitable protective clothing, gloves and eye/face protection.
• Hazardous Substances Data: 1210-96-4(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
1,5-Dimethoxy-2,4-dinitrobenzene is used as a reagent in organic synthesis for the detection of primary amines. It is utilized for its ability to react with primary amines, resulting in the formation of yellow-colored compounds, which aids in the qualitative analysis of amino groups in organic compounds.
Used in Dye Production:
In the dye industry, 1,5-Dimethoxy-2,4-dinitrobenzene is employed as a precursor in the synthesis of various dyes. Its chemical properties make it a valuable component in the creation of a range of colorants used in different applications.
Used in Pharmaceutical Production:
1,5-Dimethoxy-2,4-dinitrobenzene is also used in the pharmaceutical industry for the production of certain drugs. Its chemical structure contributes to the synthesis of medicinal compounds, highlighting its importance in the development of pharmaceuticals.
It is crucial to handle 1,5-Dimethoxy-2,4-dinitrobenzene with care due to its toxic nature and potential to cause harm upon contact with the skin, eyes, or respiratory system. Proper safety measures should be taken to minimize exposure and ensure the safe use of 1,5-Dimethoxy-2,4-dinitrobenzene in various applications.

InChI:InChI=1/C8H8N2O6/c1-15-7-3-5(9(11)12)6(10(13)14)4-8(7)16-2/h3-4H,1-2H3

Upstream product

• 3698-83-7 2,4-dichloro-1,5-dinitrobenzene 
• 124-41-4 sodium methylate 
• 64-17-5 ethanol 
• 861371-29-1 3,5-dimethoxy-2,6-dinitro-aniline 
• 7051-11-8 4-(1,1-dimethylethyl)-3-methoxyanisol 
• 4920-84-7 2,4-dimethoxynitrobenzene 
• 51652-35-8 5-methoxy-2,4-dinitrophenol 
• 77-78-1 dimethyl sulfate 
• 151-10-0 1,3-Dimethoxybenzene 
• 7697-37-2 nitric acid 
• 64-19-7 acetic acid 
• 36122-02-8 1-tert-butyl-2,4-dimethoxy-5-nitro-benzene 
• 89464-07-3 2,4,5-trinitrobromobenzene 
• 446-35-5 2,4-Difluoronitrobenzene 

Downstream Products

• 105337-28-8 1,5-dinitro-2,4-dipropoxy-benzene 
• 100876-90-2 1,5-diisobutoxy-2,4-dinitrobenzene 
• 37923-53-8 1,5-diethoxy-2,4-dinitro-benzene 
• 616-74-0 4,6-dinitroresorcinol 
• 1150-40-9 1,3-dimethoxy-2,4,6-trinitrobenzene 
• 4987-96-6 1,3-diamino-4,6-dinitrobenzene 
• 70904-65-3 1-amino-2,4-dimethoxy-5-nitrobenzene 
• 871886-01-0 N-(5-methoxy-2,4-dinitro-phenyl)-hydroxylamine 
• 56224-03-4 (5-Methoxy-2,4-dinitro-phenyl)-hydrazine 
• 56224-53-4 1,3-dihydrazino-4,6-dinitrobenzene 
• 111271-69-3 3-Nitro-4,6-dimethoxy-triphenylamin 
• 1129-15-3 4,6-dimethoxy-benzene-1,3-diamine 
• 56225-20-8 N²,N⁴-Bis-(2-diethylamino-ethyl)-5-nitro-benzene-1,2,4-triamine 
• 116779-66-9 2,4,5-trinitro-anisole 

Relevant articles and documents

2,4-dibasic miazines compound

The invention belongs to the field of medical chemistry, relates to a 2,4-dibasic miazines compound and specifically relates to a compound shown as formula (I) or a pharmaceutically acceptable salt thereof, a drug compound thereof and an application thereof in treating EGFR or/and ALK mediated diseases.

Persistent Organic Nanopores Amenable to Structural and Functional Tuning

Rigid macrocycles 2, which share a hybrid backbone and the same set of side chains while having inner cavities with different inward-pointing functional groups, undergo similar nanotubular assembly as indicated by multiple techniques including 1H NMR, fluorescence spectroscopy, and atomic force microscopy. The formation of tubular assemblies containing subnanometer pores is also attested by the different transmembrane ion-transport behavior observed for these macrocycles. Vesicle-based stopped-flow kinetic assay and single-channel electrophysiology with planar lipid bilayers show that the presence of an inward-pointing functional (X) group in the inner cavity of a macrocyclic building block exerts a major influence on the transmembrane ion-transporting preference of the corresponding self-assembling pore. Self-assembling pores with inward-pointing amino and methyl groups possess the surprising and remarkable capability of rejecting protons but are conducive to transporting larger ions. The inward-pointing groups also resulted in transmembrane pores with a different extent of positive electrostatic potentials, leading to channels having different preferences for transporting chloride ion. Results from this work demonstrate that synthetic modification at the molecular level can profoundly impact the property of otherwise structurally persistent supramolecular assemblies, with both expected tunability and suprisingly unusual behavior.

Fabrication of poly(p-phenylenebenzobisoxazole) film using a soluble poly(o -alkoxyphenylamide) as the precursor

Poly(p-phenylenebenzobisoxazole) (PPBO) is a polymer having the most excellent thermal properties among the organic polymers reported to date, and the design and the preparation of PPBO with the desired shape and form are expected to provide novel PPBO-ba

COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-DRIVEN CANCERS

The invention features compounds, pharmaceutical compositions and methods for treating patients who have an EGFR-driven cancer of Formula (I), wherein the variables are as defined herein.

COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-DRIVEN CANCERS

The invention features compounds, pharmaceutical compositions and methods for treating patients who have an EGFR-driven cancer of formula (I), wherein the variables are as defined herein.

Synthesis of crescent aromatic oligoamides

This article describes the synthetic procedures for the preparation of crescent (and helical) aromatic oligoamides developed in recent years in our laboratory. The large-scale preparation of a variety of monomers derived from various tetrasubstituted benzenes is presented. Three different strategies for constructing various oligomers consisting of meta- and meta/para-linked benzene residues are discussed. Factors affecting coupling efficiency and yields are analyzed. The developed synthetic methods have provided the basis for the preparation of longer oligomers and for the development of solid-phase synthesis.

Positive allosteric modulators of the nicotinic acetylcholine receptor

The invention provides compounds of Formula I: These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals used to treat diseases or conditions in which α7 nAChR is known to be involved.

A mild one-pot procedure for the polynitration of activated arenes. Convenient preparation of dinitro- and trinitrodialkoxybenzenes

When first treated with an excess of nitrogen dioxide alone and then in the presence of ozone at low temperature, dialkoxybenzenes are smoothly and stepwise polynitrated in a one-pot manner to afford the corresponding dinitro or trinitro derivatives in good yield.

Novel folding patterns in a family of oligoanthranilamides: Non-peptide oligomers that form extended helical secondary structures

Anthranilamide derivatives are used as the basis for a series of novel oligomers that fold into helical secondary structures in the solid state. When combined with pyridine-2,6-dicarboxylic acid and 4,6-dimethoxy-1,3-diaminobenzene subunits, oligoanthrani

Iron(III)-catalysed nitration of non-activated and moderately activated arenes with nitrogen dioxide-molecular oxygen under neutral conditions

In the presence of molecular oxygen and a catalytic amount of tris(pentane-2,4-dionato)iron(III), non-activated and moderately activated arenes, which include alkylbenzenes, halogenobenzenes, phenolic ethers, naphthalene and derivatives, can be nitrated with nitrogen dioxide at ice-bath temperature or below to give the corresponding nitro derivatives in fair to good yields. An electron-transfer mechanism has been proposed, where an activated NO2-FeIII complex plays a key role in the cyclic process for converting arenes into nitroarenes.